Total Voting Rights

RNS Number : 1209H
Hikma Pharmaceuticals Plc
06 July 2012
 



 

 

 

 

 

Hikma Pharmaceuticals PLC

Voting Rights and Capital

 

LONDON, 6 July 2012, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 5 July 2012 its capital consists of 196,857,107 ordinary shares with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.

 

- ENDS -

 

Enquiries

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2760

 



 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and nonbranded generic and inlicensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAFXKEALAEFF
UK 100

Latest directors dealings